Amedeo Smart

Free Medical Literature Service

 

Amedeo

Drug Resistance
  Free Subscription

Articles published in
Int J Antimicrob Agents
    November 2025
  1. JO DM, Oh DK, Cho KJ, Tabassum N, et al
    Understanding the role of drug efflux pumps in biofilms and virulence properties: Multiple potential strategies controlling bacterial infections.
    Int J Antimicrob Agents. 2025;66:107584.
    >> Share

  2. ZHANG J, Wang H, Ni Y, Yan Z, et al
    Comparative epidemiology and resistance mechanisms of carbapenem-, tigecycline-, and polymyxin-resistant Enterobacteriaceae in pediatric diarrhea: A cross-sectional study in 2017 and 2023.
    Int J Antimicrob Agents. 2025;66:107580.
    >> Share

  3. LIU C, Du P, Yang P, Tang Y, et al
    Long-distance transmission of tmexCD1-toprJ1 positive Klebsiella pneumoniae between humans and food animals.
    Int J Antimicrob Agents. 2025;66:107566.
    >> Share

    October 2025
  4. GAO S, Quan Y, Song S, Jin W, et al
    Corrigendum to "Disrupting bacterial metabolism by targeting LDH reverses Streptococcus suis aminoglycoside resistance" [International Journal of Antimicrobial Agents 66/6 (2025) 1-16/107599].
    Int J Antimicrob Agents. 2025 Oct 9:107631.
    >> Share

  5. PATEL RR, Arun PP, Singh SK, Singh M, et al
    Overcoming Antimicrobial Resistance: Phage Therapy as a Promising Solution to Combat ESKAPE Pathogens.
    Int J Antimicrob Agents. 2025 Oct 8:107640.
    >> Share

  6. TAI JH, Lyu YY, Zhang YS, Chu WW, et al
    Global, Regional, and National Burden of Bacterial Carbapenem Resistance from 1990 to 2021 and Predictions up to 2035.
    Int J Antimicrob Agents. 2025 Oct 8:107636.
    >> Share

  7. LIU Y, Thong S, Moreira W, Yeo JH, et al
    Clinical application of customized and non-customized bacteriophage therapy in patients with refractory/resistant bacterial infections: A systematic review and meta-analysis.
    Int J Antimicrob Agents. 2025;66:107570.
    >> Share

  8. TULLAYAPRAYOUCH K, Phuadraksa T, Luk-In S, Pornsuwan S, et al
    Development of multiplex recombinase polymerase amplification for the rapid detection of five carbapenemase (bla(KPC), bla(NDM), bla(OXA-48)-like, bla(IMP), and bla(VIM)) and 10 mcr (mcr-1 to mcr-10) genes in blood cultures.
    Int J Antimicrob Agents. 2025;66:107567.
    >> Share

  9. CHOWDHURY FR, Banari V, Lesnic V, Zhanel GG, et al
    Large scale laboratory evolution uncovers clinically relevant collateral antibiotic sensitivity.
    Int J Antimicrob Agents. 2025;66:107564.
    >> Share

  10. SASTRE-FEMENIA MA, Fernandez-Munoz A, Gomis-Font MA, Taltavull B, et al
    Spanish nationwide survey of Pseudomonas aeruginosa cefiderocol susceptibility and resistance mechanisms.
    Int J Antimicrob Agents. 2025;66:107563.
    >> Share

  11. TANG B, Meng T, Tian L, Zhong M, et al
    Within-host resistance evolution of ST15 Klebsiella pneumoniae in an ICU immunosuppressed patient under antibiotic pressure of polymyxins, ceftazidime-avibactam, and meropenem.
    Int J Antimicrob Agents. 2025;66:107554.
    >> Share

  12. KUAI J, Zhao Y, Wang R, Zhang Y, et al
    Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2025;66:107551.
    >> Share

    September 2025
  13. CURRY BN, Singh N, Gross AE, Watkins JV, et al
    Pharmacodynamic Insights to Support Pneumonia Treatment in a Patient Co-Infected with Two Carbapenem-Resistant Bacteria.
    Int J Antimicrob Agents. 2025 Sep 25:107633.
    >> Share

  14. SONG Y, Li J, Zhang Y, Su L, et al
    Biofilm Maturation in Carbapenem-resistant Pseudomonas aeruginosa Is Regulated by the sRNA PA213 and Its Corresponding Encoded Small Protein.
    Int J Antimicrob Agents. 2025 Sep 18:107625.
    >> Share

  15. HAN R, Tang C, Yu F, Li T, et al
    Extraintestinal pathogenic Escherichia coli (ExPEC) O-serotype distribution and antibiotic resistance profiles among the aging population in China: A longitudinal, multi-center study.
    Int J Antimicrob Agents. 2025 Sep 2:107607.
    >> Share

  16. LEE YL, Tan MC, Chen PJ, Shiau YR, et al
    In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022.
    Int J Antimicrob Agents. 2025;66:107550.
    >> Share

  17. ABRIL D, Solorzano P, Leal AL, Forero-Hurtado D, et al
    Ceftazidime/avibactam resistance in Enterobacter cloacae due to the acquisition of a small pHAD28-like plasmid harbouring bla(KPC-33).
    Int J Antimicrob Agents. 2025;66:107540.
    >> Share

  18. LYNCH K, Martson AG
    The importance of drug exposure in the development of cytomegalovirus resistance.
    Int J Antimicrob Agents. 2025;66:107537.
    >> Share

  19. CERCENADO E, Alcala L, Irigoyen-von-Sierakowski A, Rodriguez-Sanchez B, et al
    Activity of imipenem-relebactam, ceftolozane-tazobactam and comparators against clinical isolates of Enterobacterales and Pseudomonas aeruginosa causing severe infections in hematological and oncological patients: A prospective multicenter study.
    Int J Antimicrob Agents. 2025;66:107534.
    >> Share

  20. ZHANG XW, Huang XY, Zhou ZY, Li BL, et al
    Genetic framework and evolutionary dynamics of mcr-positive Klebsiella pneumoniae from 2000 to 2023.
    Int J Antimicrob Agents. 2025;66:107533.
    >> Share

  21. TERRILL AE, Tait JR, Rogers KE, Lee WL, et al
    Effects of different resistance mechanisms on bacterial response to meropenem, ciprofloxacin, and their combination described by next-generation mechanism-based modelling.
    Int J Antimicrob Agents. 2025;66:107528.
    >> Share

    August 2025
  22. GAO S, Quan Y, Song S, Jin W, et al
    Disrupting bacterial metabolism by targeting LDH reverses Streptococcus suis aminoglycoside resistance.
    Int J Antimicrob Agents. 2025 Aug 20:107599.
    >> Share

  23. AMARLAPUDI MR, Balasubramaniam C, Akash, Singh H, et al
    Microbiome and Antibiotic Resistance Profile of Milk and Faeces from Cattle in an Organized Dairy Production System.
    Int J Antimicrob Agents. 2025 Aug 13:107590.
    >> Share

  24. FENG X, Li S, Huang D, Tan N, et al
    Emergence of carbapenem-resistant XDR Salmonella enterica in pediatric patients in South China: a genomic perspective study.
    Int J Antimicrob Agents. 2025 Aug 6:107589.
    >> Share

  25. ZHANG Y, Li Z, Shi H, Lei Z, et al
    High-level ceftazidime-avibactam resistance by in-host evolution of bla(KPC) genes: Emergence of a novel bla(KPC-102) variant and increase of bla(KPC-33) copy number in Klebsiella pneumoniae strains from a lung transplantation recipient.
    Int J Antimicrob Agents. 2025;66:107521.
    >> Share

  26. YANG J, Yue H, Wang W, Lin C, et al
    Synergistic activity of menadione in combination with colistin against colistin-susceptible and colistin-resistant Gram-negative bacteria.
    Int J Antimicrob Agents. 2025;66:107523.
    >> Share

  27. WEI W, Lian Y, Peng Y, Kan B, et al
    Drug resistance phenotypes of clinical Klebsiella pneumoniae isolates in the past 20 years in China: A systematic review and meta-analysis.
    Int J Antimicrob Agents. 2025;66:107520.
    >> Share

  28. H ALBEHAIJANI S, Huynh T, Boyce KJ
    Cellular and genetic changes during and after fluconazole exposure in Cryptococcus neoformans.
    Int J Antimicrob Agents. 2025;66:107519.
    >> Share

  29. MALIK MA, Manzoor S, Ashraf J
    Bayesian evaluation of phage therapy efficacy against multidrug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2025;66:107508.
    >> Share

    July 2025
  30. LIN HH, Lin YT, Chen CH, Tseng KH, et al
    Prediction of methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae from Raman spectra by Artificial Intelligent Raman Detection and Identification System (AIRDIS) with machine learning.
    Int J Antimicrob Agents. 2025 Jul 30:107587.
    >> Share

  31. ELIAS R, Phelan JE, Lito L, Caneiras C, et al
    Genome-Wide Analysis and Longitudinal Study of Klebsiella pneumoniae in Portugal: Tracing the Evolution and Spread of Carbapenem Resistance.
    Int J Antimicrob Agents. 2025 Jul 30:107583.
    >> Share

  32. YAO ZC, Sun Y, Ma ZX, Chen HC, et al
    Longitudinal Analysis of Carbapenem-Resistant Escherichia coli in a Southern Chinese Hospital (2015-2021): Epidemiology, Genetics, and Resistance Mechanisms.
    Int J Antimicrob Agents. 2025 Jul 19:107577.
    >> Share

  33. WOH PY, Soengkono F, Chen Y, Hasan ZHA, et al
    Genomic insights into nontyphoidal Salmonella: Prediction of antimicrobial resistance with whole genome-based machine learning.
    Int J Antimicrob Agents. 2025 Jul 15:107575.
    >> Share

  34. CHEN Y, Hong Y, Wang X, Cheng X, et al
    Profiling of omadacycline resistance in clinical MRSA: A nationwide genomic survey and in vitro evolutionary analysis.
    Int J Antimicrob Agents. 2025;66:107499.
    >> Share

  35. JEAN SS, Lai CC, Ho SJ, Liu IM, et al
    Geographic variations in distributions of carbapenemase-encoding genes, susceptibilities, and minimum inhibitory concentrations of inpatient meropenem-resistant Enterobacterales to ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam-avibactam
    Int J Antimicrob Agents. 2025;66:107500.
    >> Share

  36. WU Z, Famous M, Stoikidou T, Bowden FES, et al
    Unravelling AMR dynamics in the rumenofaecobiome: Insights, challenges and implications for One Health.
    Int J Antimicrob Agents. 2025;66:107494.
    >> Share

    June 2025
  37. FAXEN L, Muller V, Chatzopoulou M, Lindsjo OK, et al
    Antibiotic susceptibility to new antibiotics and genetic characterisation of carbapenemase-producing Enterobacterales: low activity of cefiderocol against NDM-producing isolates.
    Int J Antimicrob Agents. 2025 Jun 17:107553.
    >> Share

  38. VECILLA DF, Gutierrez MJU, Toboso MCN, Inchaurza KZ, et al
    Genetic characterization of extensively drug-resistant bla(CTX-M-27)Shigella sonnei clusters among men who have sex with men in a region of northern Spain.
    Int J Antimicrob Agents. 2025;65:107490.
    >> Share

  39. TAIT JR, Agyeman AA, Lopez-Causape C, Deveson-Lucas D, et al
    Multiomics informed mathematical model for meropenem and tobramycin against hypermutable Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2025;65:107488.
    >> Share

    May 2025
  40. TAIE A, Gheorghe M, Amos J, Morton A, et al
    Antimicrobial Resistance Trends, Predictors, and Burden in England: A retrospective study using the Clinical Practice Research Datalink from 2015-2021.
    Int J Antimicrob Agents. 2025 May 13:107535.
    >> Share

  41. HAN X, Song M, Yu Q, Zhou J, et al
    Unveiling the Clonal Dynamics and transmission mechanism of Carbapenem-Resistant Klebsiella pneumoniae in the ICU environment.
    Int J Antimicrob Agents. 2025 May 6:107532.
    >> Share

  42. MONTERO MM, Domene-Ochoa S, Prim N, Lopez-Causape C, et al
    Pharmacodynamic interaction of apotransferrin and anti-pseudomonal antibiotics against extensively drug-resistant Pseudomonas aeruginosa in a dynamic PK/PD model.
    Int J Antimicrob Agents. 2025;65:107477.
    >> Share

  43. GAO S, Liu B, Yuan S, Quan Y, et al
    Cross-talk between signal transduction systems and metabolic networks in antibiotic resistance and tolerance.
    Int J Antimicrob Agents. 2025;65:107479.
    >> Share

    April 2025
  44. BOYS MTH, Pletzer D
    A review of recently discovered mechanisms of cephalosporin resistance in Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2025 Apr 28:107527.
    >> Share

  45. ETIENNE F, Lurier T, Yugueros-Marcos J, Mateus ALP, et al
    Is use of antimicrobial growth promoters linked to antimicrobial resistance in food-producing animals? A systematic review.
    Int J Antimicrob Agents. 2025 Apr 4:107505.
    >> Share

  46. ALLAW F, Vu Thi Lan H, Nagao M, Ndegwa L, et al
    Antibiotic shortages: An overview by the alliance for the prudent use of antibiotics (APUA).
    Int J Antimicrob Agents. 2025;65:107456.
    >> Share

  47. YANG Z, Lim TP, Mohamed Yusoff NB, Wong CSL, et al
    In vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates collected from two general hospitals in Singapore.
    Int J Antimicrob Agents. 2025;65:107447.
    >> Share

    March 2025
  48. LIAO W, Quan J, Huang L, Zhou M, et al
    Emergence of a Clinical Carbapenem Resistant Escherichia coli Co-Harboring bla(NDM-5) and mcr-1.1 on the Same Plasmid.
    Int J Antimicrob Agents. 2025 Mar 24:107495.
    >> Share

  49. AITHAL S, Toh G, Guo H, Hildon ZJ, et al
    Comparing the Knowledge, Attitudes, and Practices of Antibiotic Use and Antimicrobial Resistance for Cats and/or Dogs amongst Pet Owners in Singapore: A Cross-sectional Study.
    Int J Antimicrob Agents. 2025 Mar 9:107489.
    >> Share

  50. CHEN X, Sun Z, Chen J, Xu X, et al
    The hidden threat: Klebsiella pneumoniae may develop co-resistance to colistin and cefiderocol under pressure of colistin.
    Int J Antimicrob Agents. 2025;65:107445.
    >> Share

  51. TAVARES RDS, Tacao M, Henriques I
    Integrons are key players in the spread of beta-lactamase-encoding genes.
    Int J Antimicrob Agents. 2025;65:107421.
    >> Share

  52. ZHOU P, Gao H, Li M, Wu C, et al
    Characterization of a novel KPC-2 variant, KPC-228, conferring resistance to ceftazidime-avibactam in an ST11-KL64 hypervirulent Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2025;65:107411.
    >> Share

    February 2025
  53. CHENG Y, Zhou L, Wang D, Li X, et al
    Inhaled Alone versus Inhaled Plus Intravenous Polymyxin B for the Treatment of Pneumonia Due to Carbapenem-Resistant Gram-Negative Bacteria: A Prospective Randomized Controlled Trial.
    Int J Antimicrob Agents. 2025 Feb 27:107483.
    >> Share

  54. DONG X, Xiang Y, Shen P, Xiao Y, et al
    Clinical emergence of Providencia zhejiangensis sp. nov. and Providencia xihuensis sp. nov.: Genomic insights into antimicrobial resistance and geographical distribution.
    Int J Antimicrob Agents. 2025;65:107484.
    >> Share

  55. CHEN M, Jiang S, Sun L, Wang H, et al
    "Seesaw effect" between daptomycin and ceftobiprole in daptomycin-resistant methicillin-resistant staphylococcus aureus isolates.
    Int J Antimicrob Agents. 2025 Feb 20:107469.
    >> Share

  56. SODAGARI HR, Sohail MN, Varga C
    Temporal, regional, and demographic differences among antimicrobial-resistant domestic Campylobacter jejuni human infections across the United States, 2013-2019.
    Int J Antimicrob Agents. 2025 Feb 20:107467.
    >> Share

  57. LI Y, Liu X, Yao H, Zhao X, et al
    The evolution of carbapenem-resistant Pseudomonas aeruginosa in the COVID-19 era: a global perspective and regional insights.
    Int J Antimicrob Agents. 2025 Feb 17:107466.
    >> Share

  58. JU X, Xiong P, Yan Z, Chen G, et al
    Emergence of carbapenem-resistant Citrobacter spp. across human, animal, and water environments in China.
    Int J Antimicrob Agents. 2025 Feb 12:107463.
    >> Share

  59. FAROOQ S, Talat A, Dhariwal A, Petersen FC, et al
    Transgenerational Gut Dysbiosis: Unveiling the Dynamics of Antibiotic Resistance through Mobile Genetic Elements from Mothers to Infants.
    Int J Antimicrob Agents. 2025 Feb 5:107458.
    >> Share

  60. XIAO Y, Xu Y, Han W, Wang B, et al
    Sub-minimum inhibitory concentrations of Rifampicin Attenuate Methicillin-resistant Staphylococcus aureus Virulence by Suppressing SaeRS Two-Component System and Arginine metabolism-related pathways.
    Int J Antimicrob Agents. 2025 Feb 3:107459.
    >> Share

  61. ZHANG J, Ju Y, Li L, Hameed HMA, et al
    MtrAB two-component system is crucial for the intrinsic resistance and virulence of Mycobacterium abscessus.
    Int J Antimicrob Agents. 2025;65:107442.
    >> Share

  62. TEICHMANN L, Pasman R, Luitwieler S, Varriale C, et al
    Adaptation of Escherichia coli to ciprofloxacin and enrofloxacin: Differential proteomics of the SOS response and RecA-independent mechanisms.
    Int J Antimicrob Agents. 2025;65:107420.
    >> Share

  63. RAAIJMAKERS J, Ruth MM, Schildkraut JA, Hombergh EVD, et al
    Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system.
    Int J Antimicrob Agents. 2025;65:107423.
    >> Share

  64. XIANG X, Kong J, Zhang J, Zhang X, et al
    Multiple mechanisms mediate aztreonam-avibactam resistance in Klebsiella pneumoniae: Driven by KPC-2 and OmpK36 mutations.
    Int J Antimicrob Agents. 2025;65:107425.
    >> Share

    January 2025
  65. TRIPATHI A, Jaiswal A, Kumar D, Pandit R, et al
    Whole genome sequencing revealed high occurrence of antimicrobial resistance genes in bacteria isolated from poultry manure.
    Int J Antimicrob Agents. 2025 Jan 27:107452.
    >> Share

  66. EASWARAN M, Govindaraj RG, Naderi M, Brylinski M, et al
    Evaluating the antibacterial activity of engineered phage capital EF, CyrillicEcSw endolysin against multidrug-resistant Escherichia coli strain Sw1.
    Int J Antimicrob Agents. 2025;65:107395.
    >> Share

  67. XU L, Lu X, Li Y, Butaye P, et al
    Eliminating the tigecycline resistance RND efflux pump gene cluster tmexCD-toprJ in bacteria using CRISPR/Cas9.
    Int J Antimicrob Agents. 2025;65:107390.
    >> Share

  68. YANG W, Xu H, Zhao Y, Chen W, et al
    Identification of bla(KPC-90) in Klebsiella pneumoniae associated with ceftazidime-avibactam resistance and the translocation & truncation of resistant genes mediated by IS26.
    Int J Antimicrob Agents. 2025;65:107388.
    >> Share

  69. MATAMOROS BR, Serna C, Wedel E, Montero N, et al
    NpmC - a novel A1408 16S rRNA methyltransferase in the gut of humans and animals.
    Int J Antimicrob Agents. 2025;65:107382.
    >> Share

    December 2024
  70. ZHANG J, Du L, Shi Q, Li X, et al
    Aerosolized plus intravenous polymyxin B in comparison to intravenous polymyxin B alone for the management of HAP caused by carbapenem-resistant gram-negative bacteria: a prospective multicenter cohort study.
    Int J Antimicrob Agents. 2024 Dec 30:107427.
    >> Share

  71. WAN X, Miao R, Zhang N, Huang W, et al
    Global burden of antimicrobial resistance in lower respiratory infections in 2021: a systematic analysis.
    Int J Antimicrob Agents. 2024 Dec 27:107431.
    >> Share

  72. OKUMU NO, Muloi DM, Moodley A, Ochieng L, et al
    Epidemiology of antimicrobial resistant diarrheagenic Escherichia coli pathotypes from children, livestock and food in Dagoretti South, Nairobi Kenya.
    Int J Antimicrob Agents. 2024 Dec 24:107419.
    >> Share

  73. PLANKAOVA A, Brajerova M, Capek V, Novotna GB, et al
    Corrigendum to "Clostridioides difficile infections were predominantly driven by fluoroquinolone-resistant Clostridioides difficile ribotypes 176 and 001 in Slovakia in 2018-2019" [International Journal of Antimicrobial Agents, 62 (2023) 1-9/106824].
    Int J Antimicrob Agents. 2024 Dec 24:107408.
    >> Share

  74. LIU C, Leng B, Xie M, Jiang S, et al
    Comparing ceftazidime/avibactam and polymyxin B for treating carbapenem-resistant organisms infections: a propensity score-matched retrospective cohort study.
    Int J Antimicrob Agents. 2024 Dec 20:107418.
    >> Share

  75. SHI L, Yuan H, Xu J, Long J, et al
    The longitudinal trend and driving factors of antimicrobial resistance among Streptococcus pneumoniae worldwide.
    Int J Antimicrob Agents. 2024 Dec 20:107415.
    >> Share

  76. PENG L, Song J, Sun H, Zhang X, et al
    Molecular investigation of an epidemic dissemination of vancomycin-resistant Enterococcus faecium sequence type 80 in Guangdong Province, China.
    Int J Antimicrob Agents. 2024 Dec 19:107412.
    >> Share

  77. CHUA NGS, Goh KK, Lim TP, Tang SS, et al
    Individualized Antimicrobial Therapy using Antibiotic Combination Testing and Therapeutic Drug Monitoring to Treat Carbapenem-Resistant Acinetobacter baumannii Infection.
    Int J Antimicrob Agents. 2024 Dec 19:107410.
    >> Share

  78. NKENE I, Alapati S, Ribeiro A, Okoliegbe I, et al
    Genomic and growth fitness study of extended-spectrum beta-lactamase-producing Escherichia coli from bloodstream infections after introduction of a national 4C antimicrobial stewardship policy in Scotland.
    Int J Antimicrob Agents. 2024;64:107380.
    >> Share

  79. YANG YS, Lee YL, Liu YM, Kuo CF, et al
    Acquired bla(CfxA-3) carried by a conjugative transposon or duplicated intrinsic bla(CME-3) mediates cefiderocol resistance in Elizabethkingia anophelis clinical isolates.
    Int J Antimicrob Agents. 2024;64:107378.
    >> Share

  80. JEAN SS, Ko WC, Liu IM, Hsieh PC, et al
    Geographic differences in susceptibility profiles of potential non-class B carbapenemase-producing Enterobacterales isolates against ceftazidime-avibactam, meropenem-vaborbactam, colistin, amikacin, gentamicin, and tigecycline: Data from the Antimicro
    Int J Antimicrob Agents. 2024;64:107363.
    >> Share

  81. CHEN PK, Liu CY, Kuo HY, Lee YT, et al
    Emergence of extensively-drug-resistant hypervirulent Acinetobacter baumannii isolated from patients with bacteraemia: bacterial phenotype and virulence analysis.
    Int J Antimicrob Agents. 2024;64:107358.
    >> Share

    November 2024
  82. YANG MJ, Li MJ, Huang LD, Zhang XW, et al
    Response regulator protein CiaR regulates the transcription of ccn-microRNAs and beta-lactam antibiotic resistance conversion of Streptococcus pneumoniae.
    Int J Antimicrob Agents. 2024 Nov 18:107387.
    >> Share

  83. DARWICHE FI, Hussein HM, Harb SB, Nahhal S, et al
    Investigating an outbreak of extensively drug-resistant Acinetobacter baumannii in a tertiary healthcare centre in lebanon using next-generation sequencing.
    Int J Antimicrob Agents. 2024;64:107353.
    >> Share

  84. NGUYEN HK, Duke MM, Grayton QE, Broberg CA, et al
    Impact of nitric oxide donors on capsule, biofilm and resistance profiles of Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;64:107339.
    >> Share

  85. GENG X, Li Y, Hao R, Xu C, et al
    Isobavachalcone enhances sensitivity of colistin-resistant Klebsiella pneumoniae: In vitro and in vivo proof-of-concept studies.
    Int J Antimicrob Agents. 2024;64:107338.
    >> Share

  86. ZHANG F, Li Z, Liu X, Li Z, et al
    In-host intra- and inter-species transfer of bla(KPC-2) and bla(NDM-1) in Serratia marcescens and its local and global epidemiology.
    Int J Antimicrob Agents. 2024;64:107327.
    >> Share

    October 2024
  87. LIU W, Wang Z, Huang Y, Liu Y, et al
    Acetylshikonin reduces the spread of antibiotic resistance via plasmid conjugation.
    Int J Antimicrob Agents. 2024 Oct 29:107370.
    >> Share

  88. OLIVA A, Curtolo A, Falletta A, Sacco F, et al
    Efficacy of fosfomycin-containing regimens in treating severe infections caused by KPC-producing Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii in critically ill patients.
    Int J Antimicrob Agents. 2024 Oct 26:107365.
    >> Share

  89. ZHOU Y, Yang Y, Wu C, Zhou P, et al
    LuxS/AI-2 system facilitate the dissemination of antibiotic-resistant plasmids in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024 Oct 23:107361.
    >> Share

  90. CHEN Y, Li W, Liu X, Chen Y, et al
    Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Klebsiella pneumoniae with Ceftazidime-Avibactam-Based Regimens: a case report.
    Int J Antimicrob Agents. 2024 Oct 8:107356.
    >> Share

  91. LIU H, Zhang Y, Zhong Z, Gong Y, et al
    Immunomodulator AS101 restores colistin susceptibility of clinical colistin-resistant Escherichia coli and Klebsiella pneumoniae in vitro and in vivo.
    Int J Antimicrob Agents. 2024;64:107285.
    >> Share

  92. DING P, Li H, Nan Y, Liu C, et al
    Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia.
    Int J Antimicrob Agents. 2024;64:107293.
    >> Share

  93. WAN TW, Huang YT, Lai JH, Chao QT, et al
    The emergence of transposon-driven multidrug resistance in invasive nontypeable Haemophilus influenzae over the last decade.
    Int J Antimicrob Agents. 2024;64:107319.
    >> Share

  94. MAJDI C, Duvauchelle V, Seghir M, Benimelis D, et al
    Investigation of PhoP response regulator inhibition to overcome resistance in Gram-negative clinical bacteria.
    Int J Antimicrob Agents. 2024;64:107298.
    >> Share

    September 2024
  95. XU C, Zeng F, Xu Q, Yang Y, et al
    Effectiveness of combination therapy with intrathecal or intraventricular administration of polymyxin B for hospital-acquired central nervous system infections caused by carbapenem-resistant Acinetobacter baumannii: a retrospective study.
    Int J Antimicrob Agents. 2024 Sep 21:107334.
    >> Share

  96. WU Y, Chen J, Zhang G, Li J, et al
    In vitro activities of the essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin, and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: a multicenter study in China, 2021.
    Int J Antimicrob Agents. 2024 Sep 18:107341.
    >> Share

  97. ZHANG M, Yang S, Liu Y, Zou Z, et al
    Anti-cancer agent 5-fluorouracil reverses meropenem resistance in carbapenem-resistant Gram-negative pathogens.
    Int J Antimicrob Agents. 2024 Sep 16:107337.
    >> Share

  98. ZENG S, Kong Q, Wu X, Duan M, et al
    Antibiotic Resistance of Helicobacter pylori in Mainland China: A Focus on Geographic Differences through Systematic Review and Meta-analysis.
    Int J Antimicrob Agents. 2024 Sep 6:107325.
    >> Share

  99. WEI Y, Luo H, Chen X, Yan Q, et al
    Epidemiology of subsequent Carbapenem-Resistant Enterobacterales (CRE) infection among rectal carriers: a meta-analysis of incidence, risk factors and their association with geographic region and age.
    Int J Antimicrob Agents. 2024 Sep 6:107335.
    >> Share

  100. WANG WY, Chiu CF, Tsao SM, Lee YL, et al
    Accurate prediction of antimicrobial resistance and genetic marker of Staphylococcus aureus clinical isolates using MALDI-TOF MS and machine learning - Across DRIAMS and Taiwan database.
    Int J Antimicrob Agents. 2024 Sep 5:107329.
    >> Share

  101. BULMAN ZP, Cao L, Curry BN, Biagi M, et al
    Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: a retrospective cohort study.
    Int J Antimicrob Agents. 2024 Sep 4:107321.
    >> Share

  102. PADASAS-ADALLA CS, Ortega-Kindica RCMH, Lomeli-Ortega CO, Tabugo SRM, et al
    A metagenomics-based approach to decipher the resistome and mobilome of two seahorse species, Hippocampus barbouri and Hippocampus comes.
    Int J Antimicrob Agents. 2024;64:107296.
    >> Share

  103. LIU S, Yuan D, Zhou Y, Wang B, et al
    Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations.
    Int J Antimicrob Agents. 2024;64:107294.
    >> Share

  104. ZHANG Z, Ren R, Peng C, Ji Y, et al
    Genomic characterisation of a multidrug-resistant Klebsiella pneumoniae co-harbouring bla(NDM-1), bla(KPC-2), and tet(A) isolated from the bloodstream infections of patients.
    Int J Antimicrob Agents. 2024;64:107290.
    >> Share

  105. ZHANG P, Hu J, Wu W, Shi W, et al
    Evolutionary adaptation of KPC-2-producing Pseudomonas aeruginosa high-risk sequence type 463 in a lung transplant patient.
    Int J Antimicrob Agents. 2024;64:107279.
    >> Share

  106. EUZEN V, Xhaard A, Berreira-Ibraim S, Deville L, et al
    Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant.
    Int J Antimicrob Agents. 2024;64:107281.
    >> Share

  107. LI P, Xu Q, Ding L, Zhang X, et al
    Q48K mutation in the type IB nitroreductase NrmA is responsible for nitrofurantoin resistance in Enterococcus faecium.
    Int J Antimicrob Agents. 2024;64:107277.
    >> Share

  108. JAMIN C, Notermans DW, Beuken E, Maat I, et al
    KPC-85, a carbapenemase-producing and ceftazidime-avibactam-resistant KPC-3 variant found in Klebsiella pneumoniae ST512 in the Netherlands.
    Int J Antimicrob Agents. 2024;64:107271.
    >> Share

  109. HAN X, Yao J, He J, Liu H, et al
    Clinical and laboratory insights into the threat of hypervirulent Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;64:107275.
    >> Share

  110. YU Y, Li X, Wu Y, Lou N, et al
    Global prevalence of fosfomycin resistance genes fosA and fosB in multidrug-resistant bacteria.
    Int J Antimicrob Agents. 2024;64:107272.
    >> Share

  111. KURKCU MF, Yapalak ZL, Var A, Atilan K, et al
    Investigation of Mycobacterium tuberculosis complex isolates isolated from various clinical samples and their antimycobacterial resistance status: A ten-year retrospective study.
    Int J Antimicrob Agents. 2024;64:107269.
    >> Share

  112. TANG C, Shen S, Yang W, Shi Q, et al
    Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance.
    Int J Antimicrob Agents. 2024;64:107265.
    >> Share

  113. RODRIGUEZ-RUIZ JP, Lin Q, Van Heirstraeten L, Lammens C, et al
    Long-term effects of ciprofloxacin treatment on the gastrointestinal and oropharyngeal microbiome are more pronounced after longer antibiotic courses.
    Int J Antimicrob Agents. 2024;64:107259.
    >> Share

  114. TELLAPRAGADA C, Razavi M, Peris PS, Jonsson P, et al
    Resistance to aztreonam-avibactam among clinical isolates of Escherichia coli is primarily mediated by altered penicillin-binding protein 3 and impermeability.
    Int J Antimicrob Agents. 2024;64:107256.
    >> Share

    August 2024
  115. RAGHAVAN S, Kim KS
    Host immunomodulation strategies to combat pandemic-associated antimicrobial-resistant secondary bacterial infections.
    Int J Antimicrob Agents. 2024 Aug 19:107308.
    >> Share

  116. DE MEDEIROS RC, Barros Dos Santos KT, Costa-Lourenco APR, Skaf LB, et al
    Neisseria gonorrhoeae ST-1901 in Rio de Janeiro from 2006 to 2022: phylogeny and antimicrobial resistance evolution of a well-succeeded pathogen.
    Int J Antimicrob Agents. 2024 Aug 12:107299.
    >> Share

  117. CHOU SH, Chuang C, Juan CH, Ho YC, et al
    Mechanisms and fitness of ceftazidime/avibactam-resistant Klebsiella pneumoniae clinical strains in Taiwan.
    Int J Antimicrob Agents. 2024;64:107244.
    >> Share

  118. GARCIA-FERNANDEZ S, Rodriguez-Grande J, Siller-Ruiz M, Fraile-Valcarcel N, et al
    Within-host transition to GES-55 during a GES-6-producing Serratia marcescens outbreak: Emergence of ceftazidime-avibactam resistance and increased susceptibility to carbapenems.
    Int J Antimicrob Agents. 2024;64:107257.
    >> Share

  119. WANG M, Hao M, Cui X, Liu M, et al
    Tracking emergence and outbreak of Klebsiella pneumoniae co-producing NDM-1 and KPC-2 after sulfamethoxazole-trimethoprim treatment: Insights from genetic analysis.
    Int J Antimicrob Agents. 2024;64:107237.
    >> Share

  120. LIU S, Zhou H, Kong J, Chen H, et al
    Verapamil increases susceptibility of colistin-resistant Acinetobacter baumannii to colistin.
    Int J Antimicrob Agents. 2024;64:107233.
    >> Share

  121. TANG C, Shen S, Yang W, Shi Q, et al
    Dynamic evolution of ceftazidime-avibactam resistance from a single patient through the IncX3_NDM-5 plasmid transfer and bla(KPC) mutation.
    Int J Antimicrob Agents. 2024;64:107228.
    >> Share

  122. LIAO W, Wang X, Wang Y, Ma P, et al
    Noncanonical mutations in ribosome nascent peptide exit tunnel confer clarithromycin resistance in Mycobacterium abscessus complex.
    Int J Antimicrob Agents. 2024;64:107223.
    >> Share

  123. WANG WX, Wu JZ, Zhang BL, Yu JY, et al
    Phage therapy combats pan drug-resistant Acinetobacter baumannii infection safely and efficiently.
    Int J Antimicrob Agents. 2024;64:107220.
    >> Share

  124. WU M, Dong Y, Zeng L, Lin Y, et al
    CRF08_BC subtype is more prone to ART failure and new-generation NNRTI-resistance under long-term first-line ART.
    Int J Antimicrob Agents. 2024;64:107215.
    >> Share

  125. LAI YC, Lin LW, Lee YL
    Emergence of ceftazidime-avibactam resistance through in-vivo bla(KPC-2) to bla(KPC-33) conversion during treatment of ST11 Klebsiella pneumoniae associated infections.
    Int J Antimicrob Agents. 2024;64:107213.
    >> Share

  126. YANG W, Chen J, Yang F, Ji P, et al
    Identification of a novel Providencia species showing multi-drug-resistant in three patients with hospital-acquired infection.
    Int J Antimicrob Agents. 2024;64:107211.
    >> Share

  127. KIEFFER N, Guzman-Puche J
    The importance of genomic context in interpreting fosfomycin resistance in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;64:107210.
    >> Share

  128. GUITART-MATAS J, Sanchez-Osuna M, Saez JL, de Frutos C, et al
    Deciphering resistance mechanisms to tigecycline and colistin in Salmonella enterica isolates from animal production.
    Int J Antimicrob Agents. 2024;64:107208.
    >> Share

  129. HARA GL, Antik A, Aguirre S, Giuliano C, et al
    The effect of the COVID-19 pandemic on the incidence and resistance of Gram-negative bacilli and antimicrobial consumption in the intensive care units of a referral hospital in Buenos Aires.
    Int J Antimicrob Agents. 2024;64:107203.
    >> Share

  130. ZHUANG Y, Li X, Wu Y, Jia H, et al
    Colistin resistance landscape: insights into the global spread of mcr-carrying Gram-negative bacteria.
    Int J Antimicrob Agents. 2024;64:107207.
    >> Share

  131. RARO OHF, Bouvier M, Kerbol A, Poirel L, et al
    MultiRapid ATB NP test for detecting concomitant susceptibility and resistance of last-resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections.
    Int J Antimicrob Agents. 2024;64:107206.
    >> Share

    July 2024
  132. YADAV A, Shinde PB, Mohan H, Dhar MS, et al
    Gut colonization with antibiotic resistance Escherichia coli pathobionts leads to disease severity in ulcerative colitis.
    Int J Antimicrob Agents. 2024 Jul 29:107289.
    >> Share

  133. TANG Y, Chen X, Liu C, Xue T, et al
    Policy Text Analysis of Antimicrobial Resistance Governance in China: A Focus on National-Level Policies.
    Int J Antimicrob Agents. 2024 Jul 29:107286.
    >> Share

  134. YANG X, Wang T, Zhang B, Zhang W, et al
    Clinical Outcome Assessment of Colistin Sulfate in Children with Carbapenem-Resistant Organism Infections: First Data from China.
    Int J Antimicrob Agents. 2024 Jul 11:107273.
    >> Share

  135. TANG Y, Yang C, Liu C, Xu Y, et al
    Development of an effective meropenem/KPC-2 inhibitor combination to combat infections caused by carbapenem-resistant K. pneumoniae.
    Int J Antimicrob Agents. 2024 Jul 5:107268.
    >> Share

  136. RANDO E, Novy E, Sangiorgi F, De Pascale G, et al
    A systematic review of the pharmacokinetics and pharmacodynamics of novel beta-lactams and beta-lactam with beta-lactamase inhibitor combinations for the treatment of pneumonia caused by carbapenem-resistant Gram-negative bacteria.
    Int J Antimicrob Agents. 2024 Jul 4:107266.
    >> Share

  137. CLEMENTE T, Diotallevi S, Lolatto R, Gagliardini R, et al
    Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry.
    Int J Antimicrob Agents. 2024;64:107195.
    >> Share

  138. MESCHIARI M, Asquier-Khati A, Tiseo G, Luque-Paz D, et al
    Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Int J Antimicrob Agents. 2024;64:107186.
    >> Share

  139. CHIU LW, Ku YE, Chan FY, Lie WN, et al
    Machine learning algorithms to predict colistin-induced nephrotoxicity from electronic health records in patients with multidrug-resistant Gram-negative infection.
    Int J Antimicrob Agents. 2024;64:107175.
    >> Share

    June 2024
  140. BUHL MEJ, Sunnerhagen T, Join-Lambert O, Morris T, et al
    Antimicrobial resistance surveillance of Bacteroides fragilis isolated from blood cultures, Europe, 2022 (ReSuBacfrag).
    Int J Antimicrob Agents. 2024 Jun 26:107241.
    >> Share

  141. HU L, Zhang XT, Zeng X, Xiong LX, et al
    ISAba1 mediated intrinsic chromosomal oxacillinase amplification confers carbapenem resistance in Acinetobacter baumannii.
    Int J Antimicrob Agents. 2024 Jun 22:107258.
    >> Share

  142. XU Y, Liu D, Han P, Wang H, et al
    Rapid inference of antibiotic resistance and susceptibility for Klebsiella pneumoniae by clinical shotgun metagenomic sequencing.
    Int J Antimicrob Agents. 2024 Jun 20:107252.
    >> Share

  143. LI X, Mowlaboccus S, Jackson B, Cai C, et al
    Antimicrobial Resistance Among Clinically Significant Bacteria in Wildlife: An Overlooked One Health Concern.
    Int J Antimicrob Agents. 2024 Jun 19:107251.
    >> Share

  144. JOSHI PR, Joshi SD, Periasamy H, Bakthavatchalam YD, et al
    Novel beta-lactam/beta-lactamase inhibitor combinations show limited activity against Indian carbapenem-resistant Pseudomonas aeruginosa isolates due to conundrum of diverse resistance mechanisms.
    Int J Antimicrob Agents. 2024 Jun 19:107249.
    >> Share

  145. WANG S, Ma S, Sun S, Wang Q, et al
    Global evolutionary dynamics of virulence genes in ST11-KL47 carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024 Jun 19:107245.
    >> Share

  146. GATTI M, Virgili G, Viale P, Pea F, et al
    Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post-neurosurgical extensively/multidrug-resistant Gram-negative bacteria-related meningitis/ventriculitis in the current era of novel
    Int J Antimicrob Agents. 2024;63:107177.
    >> Share

  147. ZHOU J, Yan G, Tang C, Liu J, et al
    Emergence of ceftazidime-avibactam resistance in bla(KPC-33)-harbouring ST11 Klebsiella pneumoniae in a paediatric patient.
    Int J Antimicrob Agents. 2024;63:107163.
    >> Share

  148. BREEN SKJ, Harper M, Lopez-Causape C, Rogers KE, et al
    Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Int J Antimicrob Agents. 2024;63:107161.
    >> Share

  149. HONG Y, Chen Y, Zhang J, Zhang H, et al
    Identification of the novel fosfomycin resistance gene fosSC in Staphylococcus capitis.
    Int J Antimicrob Agents. 2024;63:107162.
    >> Share

  150. ZHAO H, Li J, Feng S, Xu L, et al
    High-throughput mutagenesis and screening approach for the identification of drug-resistant mutations in the rifampicin resistance-determining region of mycobacteria.
    Int J Antimicrob Agents. 2024;63:107158.
    >> Share

    May 2024
  151. CHEN Q, Zhang F, Bai J, Che Q, et al
    Bacteriophage-Resistant Carbapenem-Resistant Klebsiella pneumoniae Shows Reduced Antibiotic Resistance and Virulence.
    Int J Antimicrob Agents. 2024 May 27:107221.
    >> Share

  152. LAI CC, Hsueh CC, Hsu CK, Tsai YW, et al
    Disease burden and macrolide resistance of Mycoplasma pneumoniae infection in adults in Asia-Pacific region.
    Int J Antimicrob Agents. 2024 May 14:107205.
    >> Share

  153. DE OLIVEIRA HC, Santos MDM, Camillo-Andrade AC, Castelli RF, et al
    Proteomics reveals that the antifungal activity of fenbendazole against Cryptococcus neoformans requires protein kinases.
    Int J Antimicrob Agents. 2024;63:107157.
    >> Share

  154. YANG W, Tang C, Shen S, Shi Q, et al
    Spread and evolution of bla(KPC)-plasmid between Serratia marcescens and Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;63:107149.
    >> Share

  155. LIM C, Coombs GW, Daley DA, Shoby P, et al
    Whole-genome sequencing identifies MprF mutations in a genetically diverse population of daptomycin non-susceptible Staphylococcus aureus in Australia.
    Int J Antimicrob Agents. 2024;63:107144.
    >> Share

  156. XU H, Tan C, Li C, Li J, et al
    ESBL-Escherichia coli extracellular vesicles mediate bacterial resistance to beta-lactam and mediate horizontal transfer of bla(CTX-M-55).
    Int J Antimicrob Agents. 2024;63:107145.
    >> Share

  157. MONTE DFM, de Oliveira CJB
    Silent dissemination of fosfomycin resistance genes in critical-priority Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;63:107139.
    >> Share

  158. LONG H, Zhao F, Feng Y, Zong Z, et al
    Global distribution of bla(CMY-42), a gene mediating reduced susceptibility to aztreonam-avibactam and ceftazidime-avibactam, in Escherichia coli.
    Int J Antimicrob Agents. 2024;63:107141.
    >> Share

  159. MESCHIARI M, Faltoni M, Kaleci S, Tassoni G, et al
    Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience.
    Int J Antimicrob Agents. 2024;63:107134.
    >> Share

  160. MEZCORD V, Traglia GM, Pasteran F, Escalante J, et al
    Characterisation of cefiderocol-resistant spontaneous mutant variants of Klebsiella pneumoniae-producing NDM-5 with a single mutation in cirA.
    Int J Antimicrob Agents. 2024;63:107131.
    >> Share

  161. ATHANASSA Z, Manioudaki S, Petsa I, Koumaki V, et al
    Effectiveness and safety of minocycline combination therapy for the treatment of patients with ventilator-associated pneumonia due to extensively drug- or pandrug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2024;63:107129.
    >> Share

  162. WANG L, Zhou X, Lu Y, Zhang X, et al
    Levofloxacin-induced MexS mutation triggers imipenem-relebactam resistance in a KPC-producing Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2024;63:107119.
    >> Share

  163. HSU CK, Lai CC, Chen CC, Chen HJ, et al
    Evaluation of three brands of Mueller-Hinton media for broth microdilution method to determine the susceptibility of multidrug-resistant Gram-negative bacilli against eravacycline.
    Int J Antimicrob Agents. 2024;63:107117.
    >> Share

  164. AMODIO E, Pizzo S, Vella G, De Francisci V, et al
    Increase of multidrug-resistant bacteria after the COVID-19 pandemic in a major teaching Hospital in Sicily (2018-2021).
    Int J Antimicrob Agents. 2024;63:107123.
    >> Share

    April 2024
  165. RUSSO A, Gulli SP, D'Avino A, Borrazzo C, et al
    Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a multicenter clinical experience.
    Int J Antimicrob Agents. 2024 Apr 30:107190.
    >> Share

  166. ZHUANG H, Chen M, Hu D, Liu L, et al
    Role of tcaA, a potential target as a ceftobiprole resistance breaker, in MRSA beta-lactam resistance.
    Int J Antimicrob Agents. 2024 Apr 29:107185.
    >> Share

  167. FRIMODT-MOLLER N, Hansen JU, Plattner M, Huseby DL, et al
    Apramycin efficacy against carbapenem- and aminoglycoside-resistant Escherichia coli and Klebsiella pneumoniae in murine blood stream infection models.
    Int J Antimicrob Agents. 2024 Apr 21:107181.
    >> Share

  168. SALLEE L, Souchet L, Boutolleau D, Nguyen S, et al
    Amenamevir for Treating Acyclovir-Resistant or Refractory Herpes Simplex Virus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Two Case Reports.
    Int J Antimicrob Agents. 2024 Apr 10:107169.
    >> Share

  169. VO T, Pontarotti P, Rolain JM, Merhej V, et al
    Mechanisms of acquisition of vanA operon among vancomycin-resistant Staphylococcus aureus genomes: the tip of the iceberg?
    Int J Antimicrob Agents. 2024 Apr 8:107154.
    >> Share

  170. GILL K, Takamichi B, Cooper A
    Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: new data from CREDIBLE-CR with an updated meta-analysis.
    Int J Antimicrob Agents. 2024 Apr 4:107167.
    >> Share

  171. GATTI M, Cosentino F, Giannella M, Viale P, et al
    In reply to the Letter to the Editor regarding "Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis".
    Int J Antimicrob Agents. 2024 Apr 4:107168.
    >> Share

  172. MONTE DFM, de Oliveira CJB
    A 22-year Brazilian colistin resistance surveillance on Escherichia coli and Salmonella spp. originating from food-producing animals.
    Int J Antimicrob Agents. 2024;63:107114.
    >> Share

    March 2024
  173. HU J, Zha L, Yu YW, Su Q, et al
    Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections: focus on Solid Organ Transplantation Recipients.
    Int J Antimicrob Agents. 2024 Mar 19:107152.
    >> Share

  174. HO LC, Yu Chi C, You YS, Hsieh YW, et al
    Impact of the implementation of the Intelligent Antimicrobial System (iAMS) on clinical outcomes among patients with bacteraemia caused by methicillin-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2024 Mar 13:107142.
    >> Share

    February 2024
  175. KHARAT AS, Makwana N, Nasser M, Gayen S, et al
    Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
    Int J Antimicrob Agents. 2024 Feb 29:107125.
    >> Share

  176. WANG C, Bai C, Chen K, Du Q, et al
    International guidelines for the treatment of carbapenem-resistant Gram-negative bacilli infections: a comparison and evaluation.
    Int J Antimicrob Agents. 2024 Feb 26:107120.
    >> Share

  177. BOATTINI M, Bianco G, Llorente LI, Acero LA, et al
    Enterobacterales carrying chromosomal AmpC beta-lactamases in Europe (EuESCPM): epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020-2022.
    Int J Antimicrob Agents. 2024 Feb 15:107115.
    >> Share

  178. YANG L, Gao Y, Zhang J, Tian C, et al
    Antimicrobial peptide DvAMP combats carbapenem-resistant Acinetobacter baumannii infection.
    Int J Antimicrob Agents. 2024 Feb 5:107106.
    >> Share

  179. WANG JL, Lai CC, Tsai YW, Ko WC, et al
    High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-2021.
    Int J Antimicrob Agents. 2024 Feb 5:107105.
    >> Share

  180. SIVAY MV, Maksimenko LV, Nalimova TM, Nefedova AA, et al
    HIV drug resistance among patients experiencing antiretroviral therapy failure in Russia, 2019-2021.
    Int J Antimicrob Agents. 2024;63:107074.
    >> Share

  181. CHEN H, Hu P, Liu H, Liu S, et al
    Combining with domiphen bromide restores colistin efficacy against colistin-resistant Gram-negative bacteria in vitro and in vivo.
    Int J Antimicrob Agents. 2024;63:107066.
    >> Share

  182. WANG C, Zhang T, Wang Y, Wang Y, et al
    Proguanil and chlorhexidine augment the antibacterial activities of clarithromycin and rifampicin against Acinetobacter baumannii.
    Int J Antimicrob Agents. 2024;63:107065.
    >> Share

    January 2024
  183. FENG Y, Fang Q, Luo H, Li J, et al
    Safety and efficacy of a phage cocktail on murine wound infections caused by carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024 Jan 11:107088.
    >> Share

  184. HSUEH CC, Lai CC, Tsai YW, Ko WC, et al
    Poor in vitro activity of ceftazidime/avibactam against carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
    Int J Antimicrob Agents. 2024 Jan 11:107087.
    >> Share

  185. HERSHKO Y, Rannon E, Adler A, Burstein D, et al
    WarA, a remote homolog of NpmA and KamB from Nocardia wallacei, confers broad spectrum aminoglycoside resistance in Nocardia and Mycobacteria.
    Int J Antimicrob Agents. 2024 Jan 11:107089.
    >> Share

  186. MUSHTAQ S, Vickers A, Woodford N, Livermore DM, et al
    Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance.
    Int J Antimicrob Agents. 2024 Jan 2:107081.
    >> Share

  187. RATOUIT P, Malet I, Soulie C, Denis J, et al
    HIV-1 resistance mutations to integrase inhibitors impair both integration and reverse transcription steps.
    Int J Antimicrob Agents. 2024;63:107026.
    >> Share

  188. PARK S, Choi J, Shin D, Kwon KT, et al
    Conversion to colistin susceptibility by tigecycline exposure in colistin-resistant Klebsiella pneumoniae and its implications to combination therapy.
    Int J Antimicrob Agents. 2024;63:107017.
    >> Share

  189. KIM SJ, Shin JH, Kim H, Ko KS, et al
    Roles of crrAB two-component regulatory system in Klebsiella pneumoniae: growth yield, survival in initial colistin treatment stage, and virulence.
    Int J Antimicrob Agents. 2024;63:107011.
    >> Share

    December 2023
  190. DU Y, Wang Y, Geng J, Long J, et al
    Molecular Mechanism of Hfq-dependent sRNA1039 and sRNA1600 Regulating Antibiotic Resistance and Virulence in Shigella sonnei.
    Int J Antimicrob Agents. 2023 Dec 21:107070.
    >> Share

  191. YU MC, Huang CK, Hung CS, Wang CH, et al
    Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis.
    Int J Antimicrob Agents. 2023 Dec 9:107053.
    >> Share

  192. KIAROSTAMI K, Fernandez-Barat L, Battaglini D, Motos A, et al
    The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia.
    Int J Antimicrob Agents. 2023 Dec 8:107052.
    >> Share

  193. JEON E, Kim MK, Park Y
    Efficacy of the bee-venom antimicrobial peptide Osmin against sensitive and carbapenem-resistant Klebsiella pneumoniae strains.
    Int J Antimicrob Agents. 2023 Dec 8:107054.
    >> Share

  194. GATTI M, Cosentino F, Giannella M, Viale P, et al
    Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis.
    Int J Antimicrob Agents. 2023 Dec 5:107047.
    >> Share

  195. HU T, Wang S, Bing J, Zheng Q, et al
    Hotspot mutations and genomic expansion of ERG11 are major mechanisms of azole resistance in environmental and human commensal isolates of Candida tropicalis.
    Int J Antimicrob Agents. 2023;62:107010.
    >> Share

    November 2023
  196. WANG SH, Yang KY, Sheu CC, Lin YC, et al
    Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: a multicenter retrospective propensity score-matched study.
    Int J Antimicrob Agents. 2023 Nov 29:107044.
    >> Share

  197. KUANG SF, Xiang J, Chen YT, Peng XX, et al
    Exogenous pyruvate promotes gentamicin uptake to kill antibiotic-resistant Vibrio alginolyticus.
    Int J Antimicrob Agents. 2023 Nov 17:107036.
    >> Share

  198. MUKHOPADHYAY S, Zhang P, To KKW, Liu Y, et al
    Sequential treatment effects on phage-antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2023;62:106951.
    >> Share

    October 2023
  199. XU C, Zeng F, Huang Y, Xu Q, et al
    Clinical Efficacy of Ceftazidime/avibactam Combination Therapy for Severe Hospital-acquired Pulmonary Infections Caused by Carbapenem-Resistant and Difficult-to-Treat Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2023 Oct 25:107021.
    >> Share

  200. CANTON R, Gottlieb T, Coombs GW, Woo PCY, et al
    Antimicrobial surveillance: a 20-year history of the SMART approach to addressing global antimicrobial resistance into the future.
    Int J Antimicrob Agents. 2023 Oct 20:107014.
    >> Share

  201. YU J, Lin HH, Tseng KH, Lin YT, et al
    Prediction of methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae from flagged blood cultures by combining rapid Sepsityper MALDI-TOF mass spectra with machine learning.
    Int J Antimicrob Agents. 2023 Oct 4:106994.
    >> Share

  202. TAO H, Liu L, Chen X, Peng L, et al
    Coexistence of Klebsiella pneumoniae and Acinetobacter baumannii contributes to antibiotic resistance.
    Int J Antimicrob Agents. 2023 Oct 2:106993.
    >> Share

  203. WANG Q, Peng K, Liu Z, Li Y, et al
    Genomic insights into linezolid-resistant Enterococci revealed its evolutionary diversity and poxtA copy number heterogeneity.
    Int J Antimicrob Agents. 2023;62:106929.
    >> Share

  204. GUILLAMET MCV, Damulira C, Atkinson A, Fraser VJ, et al
    Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant Gram-negative bacilli in patients with sepsis and septic shock.
    Int J Antimicrob Agents. 2023;62:106913.
    >> Share

    September 2023
  205. CAI T, Novelli A, Tascini C, Stefani S, et al
    Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: a systematic review and expert opinion.
    Int J Antimicrob Agents. 2023 Sep 23:106983.
    >> Share

  206. LIU JY, Jia JJ, Liu M, Duan H, et al
    A novel indolylbenzoquinone compound HL-J6 suppresses biofilm formation and alpha-toxin secretion in methicillin-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2023 Sep 21:106972.
    >> Share

  207. CAI T, Verze P, Arcaniolo D, Pandolfo SD, et al
    ANTIBIOTIC RESISTANCE PATTERNS AMONG UROPATHOGENS IN FEMALE OUTPATIENTS AFFECTED BY UNCOMPLICATED CYSTITIS: FOCUS ON FOSFOMYCIN TROMETAMOL.
    Int J Antimicrob Agents. 2023 Sep 20:106974.
    >> Share

  208. WU JW, Quyen TLT, Hsieh YC, Chen YY, et al
    Investigation of carbapenem-resistant Klebsiella pneumoniae in Taiwan revealed strains co-harboring bla(NDM) and bla(OXA-48-like) and a novel plasmid co-carrying bla(NDM-1) and bla(OXA-181).
    Int J Antimicrob Agents. 2023 Sep 4:106964.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016